LUMO News and Press, Lumos Pharma Inc. From 11/14/22

Lumos Pharma ( NASDAQ: LUMO ), a biotech focused on rare diseases, announced Monday that its lead asset, LUM-201 met expectations in an interim analysis of two Phase 2 trials for Pediatric Growth Hormone Deficiency (PGHD). The OraGrowtH210 and OraGrowtH212 trials were design...

Lumos Pharma press release ( NASDAQ: LUMO ): Q3 GAAP EPS of -$0.86 beats by $0.15 . Revenue of $0.49M. Lumos Pharma ended the quarter on September 30, 2022 with cash and cash equivalents totaling $73.7 million compared to $94.8 million on December 31, 2021. F...

-- Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six months for the LUM-201 Dose of 1.6 mg/kg/day in the OraGrowtH210 Trial which Supports Adv...

- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) - - Interim results for approximately 50% enrollment (n=41) of OraGrowtH210 Trial demonstrated a...

AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management w...

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present a...

Lumos Pharma ( NASDAQ: LUMO ) announced Tuesday that it has received Board's approval to repurchase up to $3M of company's common shares. As of June 30, 2022, the biotech firm had approximately $79.5M of cash, cash equivalents, and marketable securities. About 8.4M sh...

-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinica...

Lumos Pharma, Inc. (LUMO) Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Lisa Miller - Senior Director of Investor Relations Richard Hawkins - Chairman and Chief Executive Officer Lori Lawley - Chief Financial Officer John M...

The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Lumos Pharma, Inc. 2022 Q2 - Results - Earnings Call Presentation